 NEW YORK, July 13, 2021 PR Newswire Hoth Therapeutics, Inc. NASDAQ: HOTH, a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces the expression of toll-like receptor 2 TLR2, one of the most critical pathways for acne pathophysiology. 